Infectious diseases affect individuals differently, with some experiencing severe illness, others showing mild symptoms, and a few remaining unaffected. The variability in response can be attributed, in part, to genetic differences among individuals. Scientists from the University of Jena, University of Marburg, and University of Würzburg in Germany have recently conducted a study, published in the journal Nature Communications, to investigate how small genetic variations between people affect the activation of the immune system.
The study, led by Professor Oliver Kurzai from the University of Würzburg and Professor Johannes Schumacher from the University of Marburg, involved researchers from the Jena Leibniz Institute for Natural Product Research and Infection Biology, Leibniz-HKI. Antje Häder and Dr. Sascha Schäuble, both from the Jena Leibniz Institute, served as the first authors of the study. Professor Oliver Kurzai leads a research group at the Leibniz-HKI and the National Reference Centre for Invasive Fungal Infections.
The researchers focused on single nucleotide polymorphisms (SNPs), which are small genetic variations where single molecules in the genome are exchanged. These SNPs can influence the response of cells to activation by bacteria or fungi and are referred to as response expression quantitative trait loci (reQTLs). Specifically, the team investigated the impact of reQTLs on monocytes, a type of immune cell.
Analysis of genetic data from 215 individuals revealed a minimum of 745 reQTLs that influence the activation of monocytes upon contact with bacteria or fungi. The influence of these genetic variations is complex and varies depending on the pathogen encountered. Certain reQTLs are more likely to affect the response to bacterial pathogens, while others are associated with the response to Aspergillus fumigatus, a common fungus. The reQTLs identified in the study regulate genes that play crucial roles in controlling fundamental immunological functions. Furthermore, these reQTLs have also been linked to other diseases such as cancer, autoimmunity, and inflammatory and infectious diseases.
Professor Oliver Kurzai emphasizes the significance of the research, stating, "Our study makes an important contribution to better understand how a patient's genetic background influences their response to infectious agents. We need to learn a lot more about this in order to move towards personalized medicine in the treatment of infectious diseases, as has been already established in cancer therapy – in other words, treatment that is individually tailored to each and every patient.”
However, the findings also underscore the complexity of translating these findings into clinical practice. Each pathogen appears to have distinct genetic markers that regulate the human immune response. This suggests that there is much more to be discovered and understood in the field of personalized medicine for infectious diseases.
The study's results open up new possibilities for personalized approaches to infectious disease treatment. By considering an individual's genetic background and the specific genetic markers associated with their immune response, healthcare providers may be able to develop tailored treatments that optimize therapeutic outcomes. Nevertheless, further research and understanding are needed to unravel the intricate relationship between genetics and immune response in infectious diseases.
The study, led by Professor Oliver Kurzai from the University of Würzburg and Professor Johannes Schumacher from the University of Marburg, involved researchers from the Jena Leibniz Institute for Natural Product Research and Infection Biology, Leibniz-HKI. Antje Häder and Dr. Sascha Schäuble, both from the Jena Leibniz Institute, served as the first authors of the study. Professor Oliver Kurzai leads a research group at the Leibniz-HKI and the National Reference Centre for Invasive Fungal Infections.
The researchers focused on single nucleotide polymorphisms (SNPs), which are small genetic variations where single molecules in the genome are exchanged. These SNPs can influence the response of cells to activation by bacteria or fungi and are referred to as response expression quantitative trait loci (reQTLs). Specifically, the team investigated the impact of reQTLs on monocytes, a type of immune cell.
Analysis of genetic data from 215 individuals revealed a minimum of 745 reQTLs that influence the activation of monocytes upon contact with bacteria or fungi. The influence of these genetic variations is complex and varies depending on the pathogen encountered. Certain reQTLs are more likely to affect the response to bacterial pathogens, while others are associated with the response to Aspergillus fumigatus, a common fungus. The reQTLs identified in the study regulate genes that play crucial roles in controlling fundamental immunological functions. Furthermore, these reQTLs have also been linked to other diseases such as cancer, autoimmunity, and inflammatory and infectious diseases.
Professor Oliver Kurzai emphasizes the significance of the research, stating, "Our study makes an important contribution to better understand how a patient's genetic background influences their response to infectious agents. We need to learn a lot more about this in order to move towards personalized medicine in the treatment of infectious diseases, as has been already established in cancer therapy – in other words, treatment that is individually tailored to each and every patient.”
However, the findings also underscore the complexity of translating these findings into clinical practice. Each pathogen appears to have distinct genetic markers that regulate the human immune response. This suggests that there is much more to be discovered and understood in the field of personalized medicine for infectious diseases.
The study's results open up new possibilities for personalized approaches to infectious disease treatment. By considering an individual's genetic background and the specific genetic markers associated with their immune response, healthcare providers may be able to develop tailored treatments that optimize therapeutic outcomes. Nevertheless, further research and understanding are needed to unravel the intricate relationship between genetics and immune response in infectious diseases.